Drug withdrawals because of adverse effects

Side Effects of Drugs Annual

Volumn 30, Issue , 2008, Pages

  Aronson, Jeffrey K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 48449090595     PISSN: 03786080     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0378-6080(08)00064-0     Document Type: Review

References (18)

1. Wysowski D.K., and Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002. The importance of reporting suspected reactions. Arch Intern Med 165 (2005) 1363-1369
2. Aronson J.K., and Ferner R.E. Clarification of terminology in drug safety. Drug Saf 28 10 (2005) 851-870
3. Bastani B., Alphs L.D., and Meltzer H.Y. Development of the Clozaril Patient Management System. Psychopharmacology (Berl) 99 Suppl (1989) S122-S125
4. Miller D., Bennett L., Hollis K., Tennis P., Cook S., and Andrews E. A patient follow-up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programme. Aliment Pharmacol Ther 24 5 (2006) 869-878
5. Spriet-Pourra C., and Auriche M. Drug withdrawal from sale. 2nd ed (1994), PJB Publications Ltd, Richmond
6. Annas G.J., and Elias S. Thalidomide and the Titanic: reconstructing the technology tragedies of the twentieth century. Am J Public Health 89 1 (1999) 98-101
7. Macdonald S. Aspirin use to be banned in under 16 year olds. BMJ 325 7371 (2002) 988
8. Laidler P., Maslin S.C., and Gilhome R.W. What's new in Osmosin and intestinal perforation?. Pathol Res Pract 180 1 (1985) 74-76
9. Lerman S.J. Why not use topical penicillin?. Pediatrics 58 2 (1976) 302
10. Stephens M.D.B. Appendix I: Drug products withdrawn from the market for safety reasons. In: Talbot J., and Waller P. (Eds). Stephens' detection of new adverse drug reactions. 5th ed (2004), John Wiley & Sons Ltd, Chichester 667-702
11. Anonymous. Chloramphenicol. Br Med J 1 5538 (1967) 484
12. Rosen C.J. The rosiglitazone story-lessons from an FDA Advisory Committee meeting. N Engl J Med 357 9 (2007) 844-846
13. Shah R.R. Drug-induced QT interval prolongation-regulatory guidance and perspectives on hERG channel studies. Novartis Found Symp 266 (2005) 251-280
14. Brown H.S., Ito K., Galetin A., and Houston J.B. Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 60 5 (2005) 508-518
15. Fung M., Thornton T., Mybeck K., Hsiao-Hui J., Hornbuckle K., and Muniz E. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960 to 1999. Drug Inf J 35 (2001) 293-317
16. Loke Y.K., Price D., Derry S., and Aronson J.K. Case reports of suspected adverse drug reactions-systematic literature survey of follow-up. BMJ 332 7537 (2006) 335-339
17. Aronson J.K. Classifying adverse drug reactions in the 21st century. In: Aronson J.K. (Ed). Side effects of drugs, annual 28 (2005), Elsevier, Amsterdam xxvii-xxxiii
18. Committee for Medicinal Products for Human Use (CHMP). Guideline on risk management systems for medicinal products for human use. 14 November 2005: EMEA/CHMP/96268/2005